Published in Medicine and Law Weekly, May 19th, 2006
"Arsenic trioxide (As2 O3 ), a valuable anticancer drug for the treatment of acute promyclocytic leukemia, may also have therapeutic potential for the treatment of solid tumors. However, its therapeutic efficacy against solid tumors is lacking even at high dosages," wrote L.Q. Luo and colleagues, Harbin Medical College.
They continued, "Other therapeutic strategies are required to enhance the efficacy of As2 O3 against solid tumors such as HCC, which is refractory to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.